

PRETERM BIRTH PREDICTION AND INTERVENTION

Michael S. Cardwell, M.D.
Department of Obstetrics & Gynecology
Paul L. Foster School of Medicine
Texas Tech University Health Sciences
Center

OBJECTIVES

- 1.** To present an overview of Preterm Birth
- 2.** To review current techniques of preterm birth prediction and intervention
- 3.** To apply current techniques of prediction and intervention to patients at risk for Preterm Birth

PRETERM BIRTH

- **Birth > 20 0/7 weeks but < 34 0/7 weeks**
- **Preterm Labor**
- **Preterm PROM**
- **Cervical insufficiency (incompetency)**
- **Not indicated preterm birth**

PRETERM BIRTH

- **U.S.A. 11.7% (MOD, year 2011)**
- **Texas 13.1% (Healthy Texas Babies)**
- **El Paso 14.2% (Healthy Texas Babies)**
- **2009: 1,984 preterm births in El Paso**

PRETERM BIRTH

- Spontaneous preterm birth is leading cause of prematurity
- 15% of all preterm birth are recurrent
- Etiology of preterm birth is heterogeneous
- Therefore, prevention and treatment must be multifactorial

Short Cervix and Preterm Birth

Women with short cervix (< 20 to 25 mm) by vaginal ultrasound examination have a 75% chance of preterm delivery!!!

Preterm Birth Prediction

- 1. History**
- 2. Cervical Length**
- 3. Fetal fibronectin**

History of Preterm Birth

- 1. non-Hispanic white: 11%**
Hispanic: 11%
African American: 17%
- 2. Number of prior preterm births: each confers a 1.5X risk in subsequent pregnancies**
- 3. Gestational age at prior preterm birth less than 32 weeks: an additional 1.5X risk**

Clinical Example

African American woman with 2 prior preterm births at 28 and 26 weeks respectively

Now pregnant; determine risk of preterm birth without intervention:

$17\% \times 1.5 \times 1.5 \times 1.5 \times 1.5 = 86\%$ risk of PTB

Cervical Length

- Vaginal ultrasound between 18-24 weeks
- Shortest of 3 measurements
- CL < 25 mm
- Funneling with short cervix is not significant, CL is utmost importance

Universal Cervical Length Screening

- **Controversial**
- **Pros: may reduce PTB rate, effective interventions are available, cost-effective**
- **Cons: quality assurance of screening test, geographic restrictions, unnecessary and unproven interventions**

ACOG's Position

“...does not mandate universal cervical length screening in women without a prior preterm birth; (however), this screening strategy may be considered.”

ACOG Practice Bulletin 130, October 2012

Fetal Fibronectin

- Glue-like protein in membranes
- Theory is that “unstable” or “leaky” membranes are associated with an increase in preterm birth risk
- Dacron swab inserted using sterile speculum in the posterior fornix or blindly in the vagina
- Do between 22-35 weeks

Fetal Fibronectin Results

- **If negative, less than 1% risk of preterm birth within the next 2 weeks**
- **If positive, approximately 16% risk of preterm birth within the next 2 weeks**

Preterm Birth Interventions

- **Recurrent PTB risk: 17-P (Makena)**
- **Short cervix by scan: Vaginal progesterone or cerclage**
- **Lifestyle changes**
- **Preterm Birth Prevention Clinic**

17-P

- **Weekly injections from 16-36 weeks**
- **FDA-approved: Makena (start by 20 6/7 weeks)**
- **ACOG-recommended (start by 24 weeks)**
- **Standard of Care**
- **Reduces recurrent preterm birth by 35%**

17-P

- **History of preterm birth**
- **Not for short cervix with no history of PTB**
- **Not for multiple gestations**
- **Not for use with vaginal progesterone**
- **Can be used in patients with a cerclage and history of preterm birth**

17-P for Your Patients

- Usually a benefit of commercial insurance plans
- Texas Medicaid: if compounding pharmacy within 50 miles, compound 17-P; if not, Makena
- Watson Pharmaceuticals, manufacturer of Makena, will provide Makena to uninsured patients, at least at the present

Know Your Compounding Pharmacy

- 1. Variability in dosage, potency, and purity**
- 2. Some patients may be allergic to oils used as the depo agent**
- 3. Gluteal abscesses have been reported, some locally and some serious**

Progesterone Gel or Suppositories

- **No history of preterm birth**
- **Short CL found on vaginal ultrasound**
- **Use until 36 weeks**
- **Reduces preterm birth by 45%**

Cervical Cerclage

- “Purse-string” stitch in cervix
- History of incompetent cervix
- Short cervix by vaginal ultrasound without a history of preterm birth
- “Stitch in time, saves nine (months)”

Useful Algorithm

- Prior loss due to CI: cerclage
- Prior preterm birth: 17-P
- Short cervix, no history, < 24 weeks: vaginal progesterone
- Prior preterm birth, on 17-P, short cervix, <24 weeks: consider cerclage

Cervical Cerclage

- **McDonald cerclage: easy and effective, 0-Prolene, 1 purse-string stitch**
- **Shirodkar: difficult to place and remove and not more effective than McDonald**
- **Best not to use Mersilene band unless you have a desire to remove stitch under anesthesia**

Cervical Cerclage

- **Prophylactic: 10-14 weeks**
- **Therapeutic: up to 24-26 weeks**
- **Remove at 36 weeks**
- **PPROM: to remove or keep, controversial**

Vaginal Progesterone

- 90 mg (gel) or 200 mg (suppository) daily
- Crinone 8%: 1 applicator vaginally q hs
- Crinone gel has a bioadhesive that keeps the gel attached to the vaginal mucosa

Preterm Birth Prevention Clinic

- Focuses on preterm birth prevention
- Uses state of the art diagnostics and therapeutics
- Based on Utah model that showed a 28% reduction in recurrent preterm birth

Manuck et al. Am J Obstet Gynecol
2011;204:320.e1-6

Goals of Preterm Birth Prevention Clinics

- 1. Reduce morbidity and mortality associated with preterm birth**
- 2. Educate patients and providers about preterm birth prediction and interventions**
- 3. Provide support to patients at risk for preterm birth**
- 4. Lower healthcare costs attributable to preterm birth**

Summary of ACOG Level A Evidence

- Singleton pregnancy with prior preterm singleton birth, give 17-P
- Short cervix (< 20 mm) before 24 weeks, give vaginal progesterone
- No progesterone in multiple gestations

Inpatient Management of Preterm Labor

- 1. Diagnosis**
- 2. Management**

Diagnosis of Preterm Labor

- **Regular uterine contractions with change in dilatation, effacement, or both**
- **Regular uterine contractions with cervical dilatation of 2 cm on admission**

ACOG Practice Bulletin 127, June 2012

Diagnostic Aids for Diagnosing PTL

- **Fetal fibronectin**
- **Cervical length per vaginal ultrasound**

No Intervention

- 30% of patients admitted with PTL will have spontaneous resolution
- 50% of patients admitted with PTL will deliver at term
- No interventions < 24 weeks or > 34 weeks (few exceptions)
- If no cervical change, do not treat contractions

Worthless PTL Interventions

- Prophylactic tocolytic therapy
- Home uterine activity monitoring
- Cerclage, unless indicated
- Narcotic sedation
- Bed rest
- Hydration
- IV antibiotics unless documented infection or positive Group B Strept status

Effective PTL Interventions

- Antenatal corticosteroids (24-34 weeks)
- Short course of tocolytic therapy during “steroid window”
- Antibiotics for positive Group B Strept status
- Magnesium sulfate for neuroprotection

Antenatal Corticosteroids

- Standard of care since NIH Consensus Conference (1992)
- Betamethasone or dexamethasone
- Administer between 24-34 weeks
- May give one additional rescue course of steroids if > 7 days since last course (ACOG, 2011)

Short Course of Tocolytic Therapy

- Use for 48 hours or less
- Beta-adrenergic receptor agonists (terbutaline).
- Calcium channel blockers (nifedipine)
- NSAIDS if less than 32 weeks (indomethacin)

ACOG Practice Bulletin 127, June 2012

Tocolytics

- **Terbutaline: limited use, beware FDA's blackbox designation**
- **NSAIDS: indomethacin 100 mg rectally then 50 mg q 6 hours**
- **Nifedipine: preferred agent, 20 mg orally , then every 3-6 hours**

Group B Strept

- **Treat if positive culture**
- **If no culture, treat pending culture**
- **If arrested PTL and positive status, must treat again prior to delivery**

Magnesium Sulfate Neuroprotection

- **Reduces cerebral palsy by 17-45%**
- **Use between 24-31 6/7 weeks**
- **3 protocols available: Crowther, Marret, and Rouse**

Rouse Protocol

- Loading dose: 6 grams
- Maintenance dose: 2 grams/hour
- Use until delivery or for 12 hours, whichever comes first
- If < 6 hours after D/C, restart maintenance dose
- If > 6 hours after D/C, reload
- Generally, do not give additional tocolytics

The End

Thanks for your attention

Questions?